Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now
We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...
Biogen (NASDAQ:BIIB) Rating Lowered to Hold at Needham & Company LLC
Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by equities research analysts at Needham & Company LLC from a “buy” ...
BioSpace3h
Facing a Dearth of Big Pharma Interest, Rare Disease Players Get Creative to Fund R&D
A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still ...
centerforbiosimilars14h
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign ...
Biogen, UCB release phase 3 data on lupus candidate dapirolizumab
Phase 3 trial of Biogen and UCB's dapirolizumab pegol shows significant improvement in lupus disease activity. Read more here ...
BioSpace16h
Biogen, UCB Reveal Details Behind Surprise Late-Stage Win in Lupus, Eyes Second Phase III
After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...
Biopharma Leaders of Color (BLOC) Announces Board of Directors and Establishes Executive Council to Expand and Enhance Offerings
Biopharma Leaders of Color (BLOC), a 501(c)(3) non-profit organization dedicated to promoting the professional advancement of people of color and growing the representation of leaders from ...
Le Lézard21h
Lupus Therapeutics Statement on Phase 3 PHOENYCS GO Positive Data in Moderate-To-Severe Systemic Lupus
WASHINGTON, Nov. 19, 2024 /PRNewswire/ -- Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance (LRA), is encouraged by the positive Phase 3 PHOENYCS GO data reported by ...